Stipple Bio’s Lonza ADC Deal | Lucid Diligence Brief
Stipple Bio’s Lonza ADC license raises the execution test for STP-100 and…
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Stipple Bio $100 million Series A
Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC Professional…
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…
Rare Disease Video Recap—November 20, 2025
This biweekly Rare Disease Video Recap covers regulatory reforms, approvals and…
Rare Disease Today—November 20, 2025
Discover this week’s Rare Disease news, featuring EU regulatory opinions,…
Oncology Today—November 17, 2025
This week in oncology, we spotlight the most relevant updates, approvals, and…
Oncology Weekly News - September 22nd 2025
Oncology Update: RGT-61159 Orphan Drug, CRB-701 Fast Track, PDS0101 Survival…
Oncology Weekly News - August 25th 2025
🔬🧬 Oncology Updates: Iza-bren FDA Breakthrough, Inhaled KB707 Data, AI in…
Oncology Weekly News - June 2nd 2025
🔬🧬 Oncology Updates: TEVIMBRA Advances, HER2+ Breakthroughs, and Global Cancer…